Media Articles Related to Vincristine
Radiation therapy chemotherapy combination improves survival in adults with low-grade brain cancer
Source: Radiology / Nuclear Medicine News From Medical News Today [2016.04.07]
Patients with a low-grade type of brain tumor called glioma who received radiation therapy plus a chemotherapy regimen, including procarbazine, lomustine and vincristine (PCV), experienced a longer...
Published Studies Related to Vincristine
Phase II study of the tetrahydropyranyl adriamycin-cyclophosphamide, vincristine, and prednisolone regimen combined with rituximab as first-line treatment for elderly patients with diffuse large B-cell lymphoma. [2011.04]
The anthracycline drug pirarubicin (tetrahydropyranyl adriamycin; THP) apparently has fewer cardiotoxic effects than doxorubicin. We previously described the benefit of the THP-COP regimen comprising cyclophosphamide, THP, vincristine, and prednisolone for elderly patients with diffuse large B-cell lymphoma (DLBCL)...
Melphalan-prednisolone and vincristine-doxorubicin-dexamethasone chemotherapy followed by prednisolone/interferon maintenance therapy for multiple myeloma: Japan Clinical Oncology Group Study, JCOG0112. [2011.04]
A multicenter phase III study for untreated multiple myeloma was conducted to investigate a switch-induction chemotherapy with melphalan-prednisolone and vincristine-doxorubicin-dexamethasone followed by randomization on maintenance therapy for patients achieving plateau... Vincristine-doxorubicin-dexamethasone/melphalan-prednisolone switch-induction therapy might be feasible and effective for Japanese patients with multiple myeloma.
Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma: 7-year follow-up results. [2010.12]
Rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) is one of the most frequently applied initial treatments for indolent B-cell non-Hodgkin lymphoma (B-NHL); however, information on its long-term outcome is limited. Untreated patients in the concurrent arm (Arm C) received six R (375 mg/m(2) ) treatments, 2 days prior to each cycle of CHOP, and patients in the sequential arm (Arm S) received 6 weekly R (375 mg/m(2) ) treatments following six cycles of CHOP...
A trial to assess the efficacy of glutamic acid in prevention of vincristine-induced neurotoxicity in pediatric malignancies: a pilot study. [2010.11]
Vincristine is considered as a backbone of therapy in the induction and consolidation phases of pediatric malignancies... This study suggests that the coadministration of oral glutamic acid with repetitive intravenous bolus injections of vincristine resulted in a reduction of its neurotoxicity.
Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. [2010.11]
BACKGROUND: Bortezomib-induced peripheral neuropathy is a dose-limiting toxicity in patients with multiple myeloma, often requiring adjustment of treatment and affecting quality of life. We investigated the molecular profiles of early-onset (within one treatment cycle) versus late-onset (after two or three treatment cycles) bortezomib-induced peripheral neuropathy and compared them with those of vincristine-induced peripheral neuropathy during the induction phase of a prospective phase 3 trial... INTERPRETATION: Our results strongly suggest an interaction between myeloma-related factors and the patient's genetic background in the development of treatment-induced peripheral neuropathy, with different molecular pathways being implicated in bortezomib-induced and vincristine-induced peripheral neuropathy. Copyright (c) 2010 Elsevier Ltd. All rights reserved.
Clinical Trials Related to Vincristine
Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia [Terminated]
This phase I trial is studying the side effects and best dose of obatoclax mesylate when
given together with vincristine sulfate, doxorubicin hydrochloride, and dexrazoxane
hydrochloride in treating young patients with relapsed or refractory solid tumors, lymphoma,
or leukemia. Obatoclax mesylate may stop the growth of cancer cells by blocking some of the
proteins needed for cell growth and causing the cells to self-destruct. Drugs used in
chemotherapy, such as vincristine sulfate, doxorubicin hydrochloride, and dexrazoxane
hydrochloride, work in different ways to stop the growth of cancer cells, either by killing
the cells or by stopping them from dividing. Giving obatoclax mesylate together with
combination chemotherapy may kill more cancer cells.
A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular Tumors [Recruiting]
In this research study we want to learn more about which treatment works better for patients
diagnosed with a vascular tumor called Kaposiform Hemangioendothelioma (KHE) or other high
risk vascular tumors such as Tufted Angioma (TA). In these tumors, the blood cells that
help your blood clot called platelets become trapped in the tumor causing swelling, pain,
and bruising. Vascular tumors can be life threatening. There are few medical treatments that
will work to shrink the vascular tumor. Some doctors will use steroids and vincristine to
try and shrink vascular tumors.
In this research study, the study doctor will compare two different drugs to see which one
will work better to help shrink your vascular tumor. One of the drugs is vincristine.
Vincristine is approved by the Food and Drug Administration (FDA) to treat people with
cancer. Vincristine is used to stop the abnormal cells from growing such as cells that make
up blood vessels.
The other drug to be used in this study is sirolimus. Sirolimus is currently approved by the
Food and Drug Administration (FDA) to prevent transplanted organ rejection. Sirolimus is not
approved by the FDA for treatment of vascular abnormalities and is considered experimental.
Sirolimus belongs to a class of drugs call 'mTOR inhibitors'. mTOR (mammilian target of
rapamycin) helps cells to grow and may also help blood vessels to grow in a more normal
fashion. Sirolimus is currently being tested in patients with vascular tumors and cancer. In
vascular tumors, we hope sirolimus will stop the blood vessel growth.
Funding Source: FDA - OOPD (Office of Orphan Products Development)
Clinical Trial of Vincristine vs. Prednisolone for Treatment of Complicated Hemangiomas [Terminated]
The goal of this study is to determine the safety and efficacy of Prednisolone and
Vincristine for treatment of large, complicated infantile hemangiomas. The diagnostic,
therapeutic and response criteria experimentally determined in this study will be used as a
framework for future infantile hemangioma studies.
Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia [Recruiting]
This pilot phase II trial studies how well vincristine sulfate liposome works in treating
patients with acute myeloid leukemia that has returned after a period of improvement or has
not responded to previous treatment. Drugs used in chemotherapy, such as vincristine sulfate
liposome, work in different ways to stop the growth of cancer cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. Liposomal
encapsulation prolongs bioavailability (proportion of drug that enters the circulation when
introduced into the body) of vincristine sulfate, and may increase its delivery to cancer
cells with fewer side effects.
To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer [Completed]
- Marqibo(Registered Trademark) is a new anticancer drug. It combines Vincristine
sulfate, which is a widely used anticancer drug, and packages it into a tiny fat bubble
known as a liposome. The goal of this is to improve the drug's ability to destroy
cancer cells and help reduce the potential side effects of treatment.
- Vincristine sulfate was originally developed from chemicals found in the periwinkle
plant and acts against multiple types of malignant cancer. It is approved for multiple
cancer types including solid tumors and blood cancers.
- Research has shown that Marqibo(Registered Trademark) is able to slow or stop the
growth of cancer cells in some adults, both alone and in combination with other
chemotherapy drugs, but more research is needed to determine its use in children.
- There has been one previous small study of Marqibo(Registered Trademark) in children.
Although some anti-cancer activity was seen, side effects and optimal dosing were not
- As is seen with standard Vincristine suflate, the most common side effect of
Marqibo(Registered Trademark) involves the nervous system. It can cause numbness and
tingling in the hands and feet. Symptoms commonly improve when the drug is discontinued
or the dose is lowered.
- To determine the safety and efficacy of Marqibo as a treatment for children who have been
diagnosed with certain types of malignant cancer that has not responded to standard
- Children and adolescents between 2 and 21 years of age who have been diagnosed with
certain types of malignant cancer that has not responded to standard treatment.
- These cancer types include solids tumors, primary brain tumors, leukemias, and
Reports of Suspected Vincristine Side Effects
Febrile Neutropenia (261),
Toxicity TO Various Agents (89),
OFF Label USE (88), more >>